534
Views
19
CrossRef citations to date
0
Altmetric
Original Articles

Long-term safety and efficacy of rituximab in 7 Japanese patients with ANCA-associated vasculitis

, , , , , & show all
Pages 603-608 | Received 15 May 2014, Accepted 25 Oct 2014, Published online: 15 Dec 2014

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (3)

Yukiko Takeyama, Nobuyuki Ono, Yuri Shirahama, Yasushi Inoue, Atsushi Tanaka, Naoyasu Ueda, Naoya Nishimura, Shuji Nagano, Ayumi Uchino, Tomoya Miyamura, Kensuke Oryoji, Hisako Inoue, Akihito Maruyama, Shun-ichiro Ota, Seiji Yoshizawa, Takuya Sawabe, Naoko Himuro, Katsuhisa Miyake, Yasutaka Kimoto, Takahiko Horiuchi, Hiroki Mitoma, Hiroaki Niiro, Ayako Takamori & Yoshifumi Tada. (2021) Rituximab maintenance therapy for patients with antineutrophil cytoplasmic antibody-associated vasculitis in Japan. Modern Rheumatology 31:2, pages 408-416.
Read now
Masayoshi Harigai, Kenji Nagasaka, Koichi Amano, Masashi Bando, Hiroaki Dobashi, Tamihiro Kawakami, Kan Kishibe, Yohko Murakawa, Joichi Usui, Takashi Wada, Eiichi Tanaka, Eishu Nango, Takeo Nakayama, Michi Tsutsumino, Kunihiro Yamagata, Sakae Homma & Yoshihiro Arimua. (2019) 2017 Clinical practice guidelines of the Japan Research Committee of the Ministry of Health, Labour, and Welfare for Intractable Vasculitis for the management of ANCA-associated vasculitis. Modern Rheumatology 29:1, pages 20-30.
Read now

Articles from other publishers (16)

Makiko Yashiro-Furuya, Shuzo Sato, Momo Akanuma, Kairi Sato, Eiji Suzuki, Takashi Kanno, Haruki Matsumoto, Jumpei Temmoku, Yuya Fujita, Naoki Matsuoka, Tomoyuki Asano, Hiroko Kobayashi, Hiroshi Watanabe & Kiyoshi Migita. (2023) Outcome of rituximab treatment in Japanese patients with ANCA-associated vasculitis in daily clinical practice: A two-centre study in Fukushima, Japan. Modern Rheumatology 33:2, pages 352-359.
Crossref
Khalaf Kridin, Noor Mruwat, Kyle T Amber & Ralf J Ludwig. (2023) Risk of infections in patients with pemphigus treated with rituximab vs. azathioprine or mycophenolate mofetil: a large-scale global cohort study. British Journal of Dermatology.
Crossref
Mohammad Amin Habibi, Samira Alesaeidi, Mohadeseh Zahedi, Samin Hakimi Rahmani, Seyed Mohammad Piri & Soheil Tavakolpour. (2022) The Efficacy and Safety of Rituximab in ANCA-Associated Vasculitis: A Systematic Review. Biology 11:12, pages 1767.
Crossref
Ashley Leong & Warren Fong. (2022) Factors associated with cytomegalovirus infection in antineutrophil cytoplasmic antibody‐associated vasculitis: A narrative review. International Journal of Rheumatic Diseases 25:12, pages 1357-1367.
Crossref
Caleb C. Ng, Aileen Sy & Emmett T. CunninghamJrJr. (2021) Rituximab for treatment of non-infectious and non-malignant orbital inflammatory disease. Journal of Ophthalmic Inflammation and Infection 11:1.
Crossref
Vincenzo G Menditto, Giulia Rossetti, Diletta Olivari, Alessia Angeletti, Marco Rocchi, Armando Gabrielli & Giovanni Pomponio. (2021) Rituximab for eosinophilic granulomatosis with polyangiitis: a systematic review of observational studies. Rheumatology 60:4, pages 1640-1650.
Crossref
Yusuke Miyazaki, Shingo Nakayamada, Satoshi Kubo, Yuichi Ishikawa, Maiko Yoshikawa, Kei Sakata, Shigeru Iwata, Ippei Miyagawa, Kazuhisa Nakano & Yoshiya Tanaka. (2020) Favorable efficacy of rituximab in ANCA-associated vasculitis patients with excessive B cell differentiation. Arthritis Research & Therapy 22:1.
Crossref
Clémence Thery-Casari, Romain Euvrard, Sabine Mainbourg, Stéphane Durupt, Quitterie Reynaud, Isabelle Durieu, Alexandre Belot, Hervé Lobbes, Natalia Cabrera & Jean-Christophe Lega. (2020) Severe infections in patients with anti-neutrophil cytoplasmic antibody-associated vasculitides receiving rituximab: A meta-analysis. Autoimmunity Reviews 19:5, pages 102505.
Crossref
E L. Nasonov, T. V. Beketova, L. P. Ananyeva, V. I. Vasilyev, S. K. Solovyev & A. S. Avdeeva. (2019) PROSPECTS FOR ANTI-B-CELL THERAPY IN IMMUNO-INFLAMMATORY RHEUMATIC DISEASES. Rheumatology Science and Practice 57, pages 1-40.
Crossref
Shuzo Sato, Makiko Yashiro, Naoki Matsuoka, Tomoyuki Asano, Hiroko Kobayashi, Hiroshi Watanabe & Kiyoshi Migita. (2018) Clinical features and outcomes in patients with elderly-onset anti-neutrophil cytoplasmic antibody-associated vasculitis. Geriatrics & Gerontology International 18:10, pages 1453-1457.
Crossref
Gizem Ayan, Sinem Nihal Esatoglu, Gulen Hatemi, Serdal Ugurlu, Emire Seyahi, Melike Melikoglu, Izzet Fresko, Huri Ozdogan, Sebahattin Yurdakul & Vedat Hamuryudan. (2018) Rituximab for anti-neutrophil cytoplasmic antibodies-associated vasculitis: experience of a single center and systematic review of non-randomized studies. Rheumatology International 38:4, pages 607-622.
Crossref
Takahiro Okazaki, Shoshi Shinagawa & Hidenori Mikage. (2017) Vasculitis syndrome-diagnosis and therapy. Journal of General and Family Medicine 18:2, pages 72-78.
Crossref
Ayako Saito, Yoichi Takeuchi, Saeko Kagaya, Yoshie Ojima, Hirotaka Fukami, Hiroyuki Sato, Ken Matsuda & Tasuku Nagasawa. (2017) Remission Induction Therapy with Rituximab for Microscopic Polyangiitis: A Feasibility Study. The Tohoku Journal of Experimental Medicine 242:1, pages 53-62.
Crossref
Shingo Nakayamada & Yoshiya Tanaka. (2016) BAFF- and APRIL-targeted therapy in systemic autoimmune diseases. Inflammation and Regeneration 36:1.
Crossref
A. Broomfield, S. A. Jones, S. M. Hughes & B. W. Bigger. (2016) The impact of the immune system on the safety and efficiency of enzyme replacement therapy in lysosomal storage disorders. Journal of Inherited Metabolic Disease 39:4, pages 499-512.
Crossref
. (2015) Rituximab. Reactions Weekly 1568:1, pages 240-240.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.